Deutsche Bank Ag\ Immunic, Inc. Transaction History

Deutsche Bank Ag\

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$3.13 - $12.25 $31,807 - $124,484	-10,162 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$9.54 - $14.26 $11,428 - $17,083	-1,198 Reduced 10.55%	10,162 $115,000
Q4 2021 Feb 11, 2022	BUY	$7.34 - $10.25 $4,345 - $6,068	592 Added 5.5%	11,360 $109,000
Q3 2021 Nov 04, 2021	BUY	$8.05 - $13.29 $12,549 - $20,719	1,559 Added 16.93%	10,768 $95,000
Q2 2021 Aug 11, 2021	BUY	$11.76 - $16.85 $66,314 - $95,017	5,639 Added 157.96%	9,209 $113,000
Q1 2021 May 13, 2021	SELL	$14.21 - $25.3 $4,859 - $8,652	-342 Reduced 8.74%	3,570 $56,000
Q4 2020 Feb 16, 2021	BUY	$14.8 - $20.37 $16,590 - $22,834	1,121 Added 40.16%	3,912 $60,000
Q3 2020 Nov 12, 2020	BUY	$11.74 - $22.0 $14,193 - $26,598	1,209 Added 76.42%	2,791 $52,000
Q2 2020 Aug 13, 2020	BUY	$5.67 - $15.86 $8,969 - $25,090	1,582 New	1,582 $19,000
Q1 2020 May 14, 2020	SELL	$4.22 - $9.8 $1,696 - $3,939	-402 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$6.4 - $10.23 $2,572 - $4,112	402 New	402 $3,000
Q3 2019 Nov 14, 2019	SELL	$10.0 - $17.01 $1,940 - $3,299	-194 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$7.88 - $33.2 $1,528 - $6,440	194 New	194 $2,000

56.2M

100

350K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $33.9M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.